MariTide
vs Zenagamtide.
Compare MariTide with amycretin, now zenagamtide, by monthly, oral, and weekly routes, receptor mechanism, trial evidence, stage, and approval status.
What is the difference?
MariTide and amycretin, now called zenagamtide, are separate investigational obesity programs designed around different mechanisms and treatment schedules. MariTide is a peptide-antibody conjugate that activates GLP-1 receptors and antagonizes GIP receptors, with monthly dosing at the center of its efficacy program. Zenagamtide activates GLP-1 and amylin receptors and is being developed as a daily tablet and weekly injection. No head-to-head trial has compared them, and neither is FDA approved.
See the useful differences first.
Start with identity, current US status, trial coverage, and the evidence relationship. Then carry the exact pair into a country-aware workspace without losing either record.
MariTide
Investigational - not FDA approved
- Route
- Subcutaneous injection
- Registry
- 27 matched NCT records
- Sponsor
- Amgen
Zenagamtide
Investigational - not FDA approved
- Route
- Once-daily oral or once-weekly subcutaneous
- Registry
- 24 matched NCT records
- Sponsor
- Novo Nordisk
MariTide vs Zenagamtide: how direct is the evidence?
No participant in the cited sources was randomized between MariTide and Zenagamtide. Identity, mechanism, route, trial design, and regulatory status can be compared. Subtracting percentages from separate studies would create a treatment effect the evidence did not test.
MariTide
GLP-1 receptor agonist + GIP receptor antagonist
- Route
- Subcutaneous injection
- Stage
- Phase 3 program active
- Status
- Investigational - not FDA approved
Two evidence records, no shared randomization.
Treat percentages as separate source records. Do not subtract them, divide them into weekly rates, or use the larger value to name a winner.
No randomized head-to-head trialZenagamtide
GLP-1 + amylin receptor agonist
- Route
- Once-daily oral or once-weekly subcutaneous
- Stage
- Phase 3 development underway
- Status
- Investigational - not FDA approved
The current exact-intervention dataset contains 268 unique NCT records across 13 tracked investigational programs. Counts describe registry coverage, not comparative evidence strength.
matched NCT records
- Recruiting
- 6
- Results posted
- 2
- Recruiting site observations
- 1581
matched NCT records
- Recruiting
- 10
- Results posted
- 0
- Recruiting site observations
- 935
Compare the named molecules, active components, sponsors, and receptor strategies.
Compare the studied route, frequency, development phase, and exact program record.
Compare exact approvals, applications, and investigational status in the jurisdiction being checked.
Treat percentages as separate source records. Do not subtract them, divide them into weekly rates, or use the larger value to name a winner.
Use only adverse-event evidence reported for the cited protocol. Separate studies cannot establish which program is safer.
No group result, receptor count, route, approval milestone, or chart position predicts the best choice for one person.
Check both programs in the same market.
Approval, trial activity, product registration, pharmacy rules, and seller authority are country specific. Open both records before treating a status from one market as valid in another.
MariTide
GLP-1 receptor agonist + GIP receptor antagonist
- Route
- Subcutaneous injection
- Stage
- Phase 3 program active
- Status
- Investigational - not FDA approved
- Featured trial anchors
- NCT05669599 · NCT06858878 · NCT07037433
Zenagamtide
GLP-1 + amylin receptor agonist
- Route
- Once-daily oral or once-weekly subcutaneous
- Stage
- Phase 3 development underway
- Status
- Investigational - not FDA approved
- Featured trial anchors
- NCT06049329 · NCT07503210 · NCT07668414
Compare the field, then read the limit.
The pair represents two convenience strategies attracting early interest: less-frequent injections and an oral formulation. Convenience cannot be decided from route labels alone. Trial duration, escalation, tolerability, adherence, manufacturing, approval, and the final commercial presentation all remain relevant, while a monthly or oral schedule under study is not yet an approved consumer option.
| Field | MariTide | Zenagamtide | How to interpret it |
|---|---|---|---|
| Mechanism | GLP-1 receptor agonist plus GIP receptor antagonist | GLP-1 and amylin receptor agonist | Both use GLP-1 biology, but their second pathway and molecular format are different. |
| Route studied | Monthly subcutaneous lead schedule | Once-daily oral and once-weekly subcutaneous formulations | The programs test different ways to reduce treatment burden, none of which is an approved label yet. |
| Evidence anchor | Up to 19.9% at 52 weeks in Phase 2 participants without diabetes | Up to 14.5% at 36 weeks in a Phase 2 subcutaneous group with type 2 diabetes | Different populations, routes, durations, and study designs rule out a percentage ranking. |
| Name to follow | MariTide, formerly AMG 133 | Zenagamtide, formerly amycretin | Former names remain useful search aliases, while current names connect to newer records. |
Why the headline numbers do not name a winner.
MariTide's clearest efficacy record comes from a 52-week Phase 2 obesity cohort without diabetes. Zenagamtide's later 36-week Phase 2 results cited here came from people with type 2 diabetes and included separate oral and subcutaneous groups. The earlier 13.1% oral signal came from a small Phase 1 cohort. These records can explain development momentum but not comparative superiority.
Keep the comparison honest.
- 01
Compare convenience as a research question, not as a settled claim about an approved monthly injection or daily pill.
- 02
Keep zenagamtide's oral and subcutaneous evidence separate, especially when quoting the early 12-week signal.
- 03
Do not rank the programs by headline weight-loss percentages taken from different populations and durations.
A country-specific approval, clinical trial, or matching name does not authenticate an online product or establish access elsewhere. This page contains no treatment recommendation, buying route, personal-use protocol, or affiliate link.
Open the safety and status guide →